Newly Diagnosed Diffuse Large B Cell Lymphoma clinical trials

Explore recruiting newly diagnosed diffuse large b cell lymphoma clinical trials.

Recruiting newly diagnosed diffuse large b cell lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Newly Diagnosed Diffuse Large B Cell Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Epi-RCHOP A Phase Ib-II Study of tazemetostat (EPZ-6438) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or high risk Follicular Lymphoma (FL) patients treated by R-CHOP

Belgium, France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2)

Spain, Belgium, Bulgaria, Greece, Denmark, Slovakia +10 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) [frontMIND]

Spain, Slovakia, Italy, Czechia, Austria, Hungary +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Newly Diagnosed Diffuse Large B Cell Lymphoma trials by city

Newly Diagnosed Diffuse Large B Cell Lymphoma in Toronto Newly Diagnosed Diffuse Large B Cell Lymphoma in Vancouver Newly Diagnosed Diffuse Large B Cell Lymphoma in Montreal Newly Diagnosed Diffuse Large B Cell Lymphoma in Calgary Newly Diagnosed Diffuse Large B Cell Lymphoma in Edmonton Newly Diagnosed Diffuse Large B Cell Lymphoma in Ottawa Newly Diagnosed Diffuse Large B Cell Lymphoma in Winnipeg Newly Diagnosed Diffuse Large B Cell Lymphoma in Quebec City Newly Diagnosed Diffuse Large B Cell Lymphoma in Hamilton Newly Diagnosed Diffuse Large B Cell Lymphoma in Kitchener Newly Diagnosed Diffuse Large B Cell Lymphoma in London Newly Diagnosed Diffuse Large B Cell Lymphoma in Halifax Newly Diagnosed Diffuse Large B Cell Lymphoma in New York Newly Diagnosed Diffuse Large B Cell Lymphoma in Los Angeles Newly Diagnosed Diffuse Large B Cell Lymphoma in Chicago Newly Diagnosed Diffuse Large B Cell Lymphoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease